Cargando…
Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer
BACKGROUND: Real-world disease models spanning multiple treatment lines can provide insight into the (cost) effectiveness of treatment sequences in clinical practice. OBJECTIVE: Our objective was to explore whether a disease model based solely on real-world data (RWD) could be used to estimate the e...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114194/ https://www.ncbi.nlm.nih.gov/pubmed/35314962 http://dx.doi.org/10.1007/s40801-022-00294-7 |
_version_ | 1784709727083560960 |
---|---|
author | Holleman, Marscha S. Huygens, Simone A. Al, Maiwenn J. Kuppen, Malou C. P. Westgeest, Hans M. van den Bergh, Alfonsus C. M. Bergman, Andries M. van den Eertwegh, Alfonsus J. M. Hendriks, Mathijs P. Lampe, Menuhin I. Mehra, Niven van Moorselaar, Reindert J. A. van Oort, Inge M. Somford, Diederik M. de Wit, Ronald van de Wouw, Agnes J. Gerritsen, Winald R. Groot, Carin A. Uyl-de |
author_facet | Holleman, Marscha S. Huygens, Simone A. Al, Maiwenn J. Kuppen, Malou C. P. Westgeest, Hans M. van den Bergh, Alfonsus C. M. Bergman, Andries M. van den Eertwegh, Alfonsus J. M. Hendriks, Mathijs P. Lampe, Menuhin I. Mehra, Niven van Moorselaar, Reindert J. A. van Oort, Inge M. Somford, Diederik M. de Wit, Ronald van de Wouw, Agnes J. Gerritsen, Winald R. Groot, Carin A. Uyl-de |
author_sort | Holleman, Marscha S. |
collection | PubMed |
description | BACKGROUND: Real-world disease models spanning multiple treatment lines can provide insight into the (cost) effectiveness of treatment sequences in clinical practice. OBJECTIVE: Our objective was to explore whether a disease model based solely on real-world data (RWD) could be used to estimate the effectiveness of treatments for patients with castration-resistant prostate cancer (CRPC) that could then be suitably used in a cost-effectiveness analysis. METHODS: We developed a patient-level simulation model using patient-level data from the Dutch CAPRI registry as input parameters. Time to event (TTE) and overall survival (OS) were estimated with multivariate regression models, and type of event (i.e., next treatment or death) was estimated with multivariate logistic regression models. To test internal validity, TTE and OS from the simulation model were compared with the observed outcomes in the registry. RESULTS: Although patient characteristics and survival outcomes of the simulated data were comparable to those in the observed data (median OS 20.6 vs. 19.8 months, respectively), the disease model was less accurate in estimating differences between treatments (median OS simulated vs. observed population: 18.6 vs. 17.9 [abiraterone acetate plus prednisone], 24.0 vs. 25.0 [enzalutamide], 20.2 vs. 18.7 [docetaxel], and 20.0 vs. 23.8 months [radium-223]). CONCLUSIONS: Overall, the disease model accurately approximated the observed data in the total CRPC population. However, the disease model was unable to predict differences in survival between treatments due to unobserved differences. Therefore, the model is not suitable for cost-effectiveness analysis of CRPC treatment. Using a combination of RWD and data from randomised controlled trials to estimate treatment effectiveness may improve the model. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40801-022-00294-7. |
format | Online Article Text |
id | pubmed-9114194 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-91141942022-05-19 Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer Holleman, Marscha S. Huygens, Simone A. Al, Maiwenn J. Kuppen, Malou C. P. Westgeest, Hans M. van den Bergh, Alfonsus C. M. Bergman, Andries M. van den Eertwegh, Alfonsus J. M. Hendriks, Mathijs P. Lampe, Menuhin I. Mehra, Niven van Moorselaar, Reindert J. A. van Oort, Inge M. Somford, Diederik M. de Wit, Ronald van de Wouw, Agnes J. Gerritsen, Winald R. Groot, Carin A. Uyl-de Drugs Real World Outcomes Original Research Article BACKGROUND: Real-world disease models spanning multiple treatment lines can provide insight into the (cost) effectiveness of treatment sequences in clinical practice. OBJECTIVE: Our objective was to explore whether a disease model based solely on real-world data (RWD) could be used to estimate the effectiveness of treatments for patients with castration-resistant prostate cancer (CRPC) that could then be suitably used in a cost-effectiveness analysis. METHODS: We developed a patient-level simulation model using patient-level data from the Dutch CAPRI registry as input parameters. Time to event (TTE) and overall survival (OS) were estimated with multivariate regression models, and type of event (i.e., next treatment or death) was estimated with multivariate logistic regression models. To test internal validity, TTE and OS from the simulation model were compared with the observed outcomes in the registry. RESULTS: Although patient characteristics and survival outcomes of the simulated data were comparable to those in the observed data (median OS 20.6 vs. 19.8 months, respectively), the disease model was less accurate in estimating differences between treatments (median OS simulated vs. observed population: 18.6 vs. 17.9 [abiraterone acetate plus prednisone], 24.0 vs. 25.0 [enzalutamide], 20.2 vs. 18.7 [docetaxel], and 20.0 vs. 23.8 months [radium-223]). CONCLUSIONS: Overall, the disease model accurately approximated the observed data in the total CRPC population. However, the disease model was unable to predict differences in survival between treatments due to unobserved differences. Therefore, the model is not suitable for cost-effectiveness analysis of CRPC treatment. Using a combination of RWD and data from randomised controlled trials to estimate treatment effectiveness may improve the model. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40801-022-00294-7. Springer International Publishing 2022-03-21 /pmc/articles/PMC9114194/ /pubmed/35314962 http://dx.doi.org/10.1007/s40801-022-00294-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Article Holleman, Marscha S. Huygens, Simone A. Al, Maiwenn J. Kuppen, Malou C. P. Westgeest, Hans M. van den Bergh, Alfonsus C. M. Bergman, Andries M. van den Eertwegh, Alfonsus J. M. Hendriks, Mathijs P. Lampe, Menuhin I. Mehra, Niven van Moorselaar, Reindert J. A. van Oort, Inge M. Somford, Diederik M. de Wit, Ronald van de Wouw, Agnes J. Gerritsen, Winald R. Groot, Carin A. Uyl-de Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer |
title | Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer |
title_full | Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer |
title_fullStr | Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer |
title_full_unstemmed | Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer |
title_short | Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer |
title_sort | being transparent about brilliant failures: an attempt to use real-world data in a disease model for patients with castration-resistant prostate cancer |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114194/ https://www.ncbi.nlm.nih.gov/pubmed/35314962 http://dx.doi.org/10.1007/s40801-022-00294-7 |
work_keys_str_mv | AT hollemanmarschas beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT huygenssimonea beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT almaiwennj beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT kuppenmaloucp beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT westgeesthansm beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT vandenberghalfonsuscm beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT bergmanandriesm beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT vandeneertweghalfonsusjm beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT hendriksmathijsp beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT lampemenuhini beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT mehraniven beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT vanmoorselaarreindertja beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT vanoortingem beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT somforddiederikm beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT dewitronald beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT vandewouwagnesj beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT gerritsenwinaldr beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer AT grootcarinauylde beingtransparentaboutbrilliantfailuresanattempttouserealworlddatainadiseasemodelforpatientswithcastrationresistantprostatecancer |